Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus TAS-102 vs Regorafenib in Refractory Metastatic Colorectal Cancer
NCT05970705Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Started Jul 2023; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05970705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970705.